A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans

References

• 3M Company. (2013). 3M's Phase Out and New Technologies. Available at: http://www.solutions.3m.com/wps/portal/3M/en_US/PFOS/PFOA/Information/phase-out-technologies/. Last accessed: 09/25/2013.
   Google Scholar
• Adami HO, Berry SC, Breckenridge CB, Smith LL, Swenberg JA, Trichopoulos D, et al. (2011). Toxicology and epidemiology: improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci, 122, 223–34.
   PubMed Web of Science ®Google Scholar
• Alexander BH, Olsen GW, Burris JM, Mandel JH, Mandel JS. (2003). Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup Environ Med, 60, 722–9.
   PubMed Web of Science ®Google Scholar
• Alexander BH, Olsen GW. (2007). Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann Epidemiol, 17, 471–8.
   PubMed Web of Science ®Google Scholar
• Andersen ME, Clewell HJ III, Tan YM, Butenhoff JL, Olsen GW. (2006). Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys–probing the determinants of long plasma half-lives. Toxicology, 227, 156–64.
   PubMed Web of Science ®Google Scholar
• Andersen ME, Preston RJ, Maier A, Willis AM, Patterson J. (2014). Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: results of a workshop. Crit Rev Toxicol, 44, 50–63.
   PubMed Web of Science ®Google Scholar
• Barry V, Winquist A, Steenland K. (2013). Perfluorooctanoic Acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environ Health Perspect, 121, 1313–18.
   PubMed Web of Science ®Google Scholar
• Biegel LB, Hurtt ME, Frame SR, O’Connor JC, Cook JC. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci, 60, 44–55.
   PubMed Web of Science ®Google Scholar
• Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, et al. (2011). Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study. Environ Health, 10, 88.
   Web of Science ®Google Scholar
• Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, de Voogt P, et al. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the environment: terminology, classification, and origins. Integr Environ Assess Manag, 7, 513–41.
   PubMedGoogle Scholar
• Budinsky RA, Schrenk D, Simon T, Van den Berg M, Reichard JF, Silkworth JB, et al. (2014). Mode of action and dose-response framework analysis for receptor-mediated toxicity: the aryl hydrocarbon receptor as a case study. Crit Rev Toxicol, 44, 83–119.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Chang SC, Olsen GW, Thomford PJ. (2012b). Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. Toxicology, 293, 1–15.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Kennedy GL Jr, Chang SC, Olsen GW. (2012a). Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology, 298, 1–13.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Olsen GW, Pfahles-Hutchens A. (2006). The applicability of biomonitoring data for perfluorooctanesulfonate to the environmental public health continuum. Environ Health Perspect, 114, 1776–82.
   PubMed Web of Science ®Google Scholar
• Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Tully JS, Needham LL. (2007). Serum concentrations of 11 polyfluoroalkyl compounds in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES). Environ Sci Technol, 41, 2237–42.
   PubMed Web of Science ®Google Scholar
• Chang SC, Noker PE, Gorman GS, Gibson SJ, Hart JA, Ehresman DJ, Butenhoff JL. (2012). Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod Toxicol, 33, 428–40.
   PubMed Web of Science ®Google Scholar
• Consonni D, Straif K, Symons JM, Tomenson JA, van Amelsvoort LG, Sleeuwenhoek A, et al. (2013). Cancer risk among tetrafluoroethylene synthesis and polymerization workers. Am J Epidemiol, 178, 350–8.
   Google Scholar
• Cook JC, Murray SM, Frame SR, Hurtt ME. (1992). Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol, 113, 209–17.
   PubMed Web of Science ®Google Scholar
• Corton JC, Cunningham ML, Hummer BT, Lau C, Meek B, Peters JM, et al. (2014). Mode of action framework analysis for receptor-mediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARalpha) as a case study. Crit Rev Toxicol, 44, 1–49.
   PubMed Web of Science ®Google Scholar
• Cote S, Ayotte P, Dodin S, Blanchet C, Mulvad G, Petersen HS, et al. (2006). Plasma organochlorine concentrations and bone ultrasound measurements: a cross-sectional study in peri-and postmenopausal Inuit women from Greenland. Environ Health, 5, 33.
   PubMedGoogle Scholar
• Deutch B, Pedersen HS, Asmund G, Hansen JC. (2007). Contaminants, diet, plasma fatty acids and smoking in Greenland 1999–2005. Sci Total Environ, 372, 486–96.
   PubMed Web of Science ®Google Scholar
• Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Butenhoff JL. (2012). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARalpha and CAR/PXR. Toxicology, 293, 16–29.
   PubMed Web of Science ®Google Scholar
• Elcombe CR, Elcombe BM, Foster JR, Farrar DG, Jung R, Chang SC, et al. (2010). Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats following dietary exposure to ammonium perfluorooctanoate occurs through increased activation of the xenosensor nuclear receptors PPARalpha and CAR/PXR. Arch Toxicol, 84, 787–98.
   PubMed Web of Science ®Google Scholar
• Elcombe CR, Peffer RC, Wolf DC, Bailey J, Bars R, Bell D, et al. (2014). Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: a case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxicol, 44, 64–82.
   PubMed Web of Science ®Google Scholar
• Eriksen KT, Sorensen M, McLaughlin JK, Lipworth L, Tjonneland A, Overvad K, et al. (2009). Perfluorooctanoate and perfluorooctanesulfonate plasma levels and risk of cancer in the general Danish population. J Natl Cancer Inst, 101, 605–9.
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Henson DE, Hutter RV. (1998). Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med, 122, 1053–5.
   PubMed Web of Science ®Google Scholar
• Frame SR, McConnell EE. (2003). Review of proliferative lesions of the exocrine pancreas in two chronic studies in rates with ammonium perfluorooctanoate. DuPont-13788 dated October 16, 2003.
   Google Scholar
• Frisbee SJ, Brooks AP Jr, Maher A, Flensborg P, Arnold S, Fletcher T, et al. (2009). The C8 health project: design, methods, and participants. Environ Health Perspect, 117, 1873–82.
   PubMed Web of Science ®Google Scholar
• Giesy JP, Kannan K. (2001). Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol, 35, 1339–42.
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Mandel JS. (1993). Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med, 35, 950–4.
   PubMedGoogle Scholar
• Grice MM, Alexander BH, Hoffbeck R, Kampa DM. (2007). Self-reported medical conditions in perfluorooctanesulfonyl fluoride manufacturing workers. J Occup Environ Med, 49, 722–9.
   PubMed Web of Science ®Google Scholar
• Han X, Nabb DL, Russell MH, Kennedy GL, Rickard RW. (2012). Renal elimination of perfluorocarboxylates (PFCAs). Chem Res Toxicol, 25, 35–46.
   PubMed Web of Science ®Google Scholar
• Hardell E, Karrman A, van Bavel B, Bao J, Carlberg M, Hardell L. (2014). Case-control study on perfluorinated alkyl acids (PFAAs) and the risk of prostate cancer. Environ Int, 63, 35–9.
   Google Scholar
• Hardisty JF, Willson GA, Brown WR, McConnell EE, Frame SR, Gaylor DW, et al. (2010). Pathology Working Group review and evaluation of proliferative lesions of mammary gland tissues in female rats fed ammonium perfluorooctanoate (APFO) in the diet for 2 years. Drug Chem Toxicol, 33, 131–7.
   PubMed Web of Science ®Google Scholar
• HCN. (2013). Perfluorooctanoic Acid and Its Salts – Evaluation of the Carcinogenicity and Genotoxicity. The Hague: Health Council of the Netherlands (HCN).
   Google Scholar
• Hill AB. (1965). The environment and disease: association or causation?Proc R Soc Med, 58, 295–300.
   PubMed Web of Science ®Google Scholar
• Houde M, Martin JW, Letcher RJ, Solomon KR, Muir DC. (2006). Biological monitoring of polyfluoroalkyl substances: a review. Environ Sci Technol, 40, 3463–73.
   PubMed Web of Science ®Google Scholar
• IARC. (2001). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 79. Some Thyrotropic Agents. Lyon, France: International Association for Research on Cancer (IARC) Press.
   Google Scholar
• Innes KE, Wimsatt JH, Frisbee S, Ducatman AM. (2014). Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. BMC Cancer, 14, 45.
   Google Scholar
• Jain RB. (2013). Effect of pregnancy on the levels of selected perfluoroalkyl compounds for females aged 17–39 years: data from National Health and Nutrition Examination Survey 2003–2008. J Toxicol Environ Health A, 76, 409–21.
   PubMed Web of Science ®Google Scholar
• Jain RB. (2014). Contribution of diet and other factors to the levels of selected polyfluorinated compounds: data from NHANES 2003–2008. Int J Hyg Environ Health, 217, 52–61.
   PubMed Web of Science ®Google Scholar
• Jurek AM, Greenland S, Maldonado G, Church TR. (2005). Proper interpretation of non-differential misclassification effects: expectations vs. observations. Int J Epidemiol, 34, 680–7.
   PubMed Web of Science ®Google Scholar
• Jurek AM, Greenland S, Maldonado G. (2008). How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null?Int J Epidemiol, 37, 382–5.
   PubMed Web of Science ®Google Scholar
• Kannan K, Corsolini S, Falandysz J, Fillmann G, Kumar KS, Loganathan BG, et al. (2004). Perfluorooctanesulfonate and related fluorochemicals in human blood from several countries. Environ Sci Technol, 38, 4489–95.
   PubMed Web of Science ®Google Scholar
• Kato K, Wong LY, Jia LT, Kuklenyik Z, Calafat AM. (2011). Trends in exposure to polyfluoroalkyl chemicals in the U.S. Population: 1999–2008. Environ Sci Technol, 45, 8037–45.
   PubMed Web of Science ®Google Scholar
• Kennedy GL Jr, Butenhoff JL, Olsen GW, O’Connor JC, Seacat AM, Perkins RG, et al. (2004). The toxicology of perfluorooctanoate. Crit Rev Toxicol, 34, 351–84.
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, et al. (2003). PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol, 33, 655–780.
   PubMed Web of Science ®Google Scholar
• Klaunig JE, Hocevar BA, Kamendulis LM. (2012). Mode of action analysis of perfluorooctanoic acid (PFOA) tumorigenicity and human relevance. Reprod Toxicol, 33, 410–8.
   PubMed Web of Science ®Google Scholar
• Klimstra DS, Heffess CS, Oertel JE, Rosai J. (1992). Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol, 16, 815–37.
   PubMedGoogle Scholar
• La Vecchia C, Negri E. (2014). A review of epidemiological data on epilepsy, phenobarbital, and risk of liver cancer. Eur J Cancer Prev, 23, 1–7.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Kreckmann KH, Sakr CJ, Symons JM. (2008). Retrospective cohort mortality study of workers in a polymer production plant including a reference population of regional workers. Ann Epidemiol, 18, 15–22.
   PubMed Web of Science ®Google Scholar
• Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. (2013). Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid, 23, 103–10.
   PubMed Web of Science ®Google Scholar
• Lim TC, Wang B, Huang J, Deng S, Yu G. (2011). Emission inventory for PFOS in China: review of past methodologies and suggestions. ScientificWorldJournal, 11, 1963–80.
   Google Scholar
• Lissner L, Skoog I, Andersson K, Beckman N, Sundh V, Waern M, et al. (2003). Participation bias in longitudinal studies: experience from the population study of women in Gothenburg, Sweden. Scand J Prim Health Care, 21, 242–7.
   PubMed Web of Science ®Google Scholar
• Loccisano AE, Campbell JL Jr, Butenhoff JL, Andersen ME, Clewell HJ III. (2012a). Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model. Reprod Toxicol, 33, 452–67.
   PubMed Web of Science ®Google Scholar
• Loccisano AE, Campbell JL Jr, Butenhoff JL, Andersen ME, Clewell HJ III. (2012b). Evaluation of placental and lactational pharmacokinetics of PFOA and PFOS in the pregnant, lactating, fetal and neonatal rat using a physiologically based pharmacokinetic model. Reprod Toxicol, 33, 468–90.
   PubMed Web of Science ®Google Scholar
• Loccisano AE, Longnecker MP, Campbell JL Jr, Andersen ME, Clewell HJ III. (2013). Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. J Toxicol Environ Health A, 76, 25–57.
   PubMed Web of Science ®Google Scholar
• Lundin JI, Alexander BH, Olsen GW, Church TR. (2009). Ammonium perfluorooctanoate production and occupational mortality. Epidemiology, 20, 921–8.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol, 2, 875–94.
   PubMed Web of Science ®Google Scholar
• National Toxicology Program. (1997). NTP toxicology and carcinogenesis studies of tetrafluoroethylene (CAS No. 116-14-3) in F344 rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser, 450, 1–321.
   Google Scholar
• Olsen GW, Burlew MM, Marshall JC, Burris JM, Mandel JH. (2004). Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facility. J Occup Environ Med, 46, 837–46.
   Google Scholar
• Olsen GW, Burris JM, Burlew MM, Mandel JH. (2000). Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol, 23, 603–20.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR. (2007). Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect, 115, 1298–305.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. (1998). An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med, 40, 614–22.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Lange CC, Ellefson ME, Mair DC, Church TR, Goldberg CL, et al. (2012). Temporal trends of perfluoroalkyl concentrations in American Red Cross adult blood donors, 2000–2010. Environ Sci Technol, 46, 6330–8.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Logan PW, Hansen KJ, Simpson CA, Burris JM, Burlew MM, et al. (2003). An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring. AIHA J (Fairfax, Va), 64, 651–9.
   Google Scholar
• Olsen GW, Zobel LR. (2007). Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health, 81, 231–46.
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol, 82, 667–715.
   PubMed Web of Science ®Google Scholar
• Prevedouros K, Cousins IT, Buck RC, Korzeniowski SH. (2006). Sources, fate and transport of perfluorocarboxylates. Environ Sci Technol, 40, 32–44.
   PubMed Web of Science ®Google Scholar
• Richardson LC, Neri AJ, Tai E, Glenn JD. (2012). Testicular cancer: a narrative review of the role of socioeconomic position from risk to survivorship. Urol Oncol, 30, 95–101.
   PubMed Web of Science ®Google Scholar
• Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. (2007). Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med, 49, 1086–96.
   PubMed Web of Science ®Google Scholar
• Sarma AV, McLaughlin JC, Schottenfeld D. (2006). Chapter 60: Testicular cancer. In: Schottenfeld D, Fraumeni JF Jr, Eds. Cancer Epidemiology and Prevention, 3rd edition. New York: Oxford University Press 1151–65..
   Google Scholar
• Seacat AM, Thomford PJ, Butenhoff JL. (2002). Terminal observations in Sprague-Dawley rats after lifetime dietary exposure to potassium perfluorooctanesulfonate [Abstract]. Toxicologist, 66, 185.
   Google Scholar
• Shin HM, Vieira VM, Ryan PB, Detwiler R, Sanders B, Steenland K, Bartell SM. (2011a). Environmental fate and transport modeling for perfluorooctanoic acid emitted from the Washington Works Facility in West Virginia. Environ Sci Technol, 45, 1435–42.
   PubMed Web of Science ®Google Scholar
• Shin HM, Vieira VM, Ryan PB, Steenland K, Bartell SM. (2011b). Retrospective exposure estimation and predicted versus observed serum perfluorooctanoic acid concentrations for participants in the C8 Health Project. Environ Health Perspect, 119, 1760–5.
   PubMed Web of Science ®Google Scholar
• Sibinski LJ. (1987). Two year oral (diet) toxicity/carcinogenicity study of fluorochemical FC-143 in rats. Experiment No. 0281CR0012. Report prepared for 3M, St. Paul, Minnesota by Riker Laboratories, Inc. U.S. EPA Public Docket AR-226–0437, Washington, DC.
   Google Scholar
• Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, et al. (2003). Cancer incidence in the US radiologic technologists health study, 1983–1998. Cancer, 97, 3080–9.
   PubMed Web of Science ®Google Scholar
• Steenland K, Woskie S. (2012). Cohort mortality study of workers exposed to perfluorooctanoic acid. Am J Epidemiol, 176, 909–17.
   PubMed Web of Science ®Google Scholar
• Sykes G. (1987). Two-year toxicology/carcinogenicity study of fluorochemical FC-143 in rats. Memo. From G Sykes to C Reinhardt, Haskell Lab. Toxicol Ind Med. Dated October 29, 1987. As cited in: Draft Risk Assessment of the Potential Human Health Effects Associated with Exposure to Perfluorooctanoic Acid and its Salts. U.S. EPA Office of Pollution Prevention and Toxics Risk Assessment Division, Washington, DC, January 4, 2005.
   Google Scholar
• Tan YM, Clewell HJ III, Andersen ME. (2008). Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol Lett, 177, 38–47.
   PubMed Web of Science ®Google Scholar
• U.S. EPA. (2006). 2010/2015 PFOA Stewardship Program. Available at: http://www.epa.gov/opptintr/pfoa/pubs/stewardship/. Last updated: January 16, 2013.
   Google Scholar
• Ubel FA, Sorenson SD, Roach DE. (1980). Health status of plant workers exposed to fluorochemicals–a preliminary report. Am Ind Hyg Assoc J, 41, 584–9.
   PubMed Web of Science ®Google Scholar
• Vassiliadou I, Costopoulou D, Ferderigou A, Leondiadis L. (2010). Levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in blood samples from different groups of adults living in Greece. Chemosphere, 80, 1199–206.
   PubMed Web of Science ®Google Scholar
• Vieira VM, Hoffman K, Shin HM, Weinberg JM, Webster TF, Fletcher T. (2013). Perfluorooctanoic acid exposure and cancer outcomes in a contaminated community: a geographic analysis. Environ Health Perspect, 121, 318–23.
   PubMed Web of Science ®Google Scholar
• Woskie SR, Gore R, Steenland K. (2012). Retrospective exposure assessment of perfluorooctanoic acid serum concentrations at a fluoropolymer manufacturing plant. Ann Occup Hyg, 56, 1025–37.
   PubMed Web of Science ®Google Scholar
• Yeung LW, Guruge KS, Taniyasu S, Yamashita N, Angus PW, Herath CB. (2013). Profiles of perfluoroalkyl substances in the liver and serum of patients with liver cancer and cirrhosis in Australia. Ecotoxicol Environ Saf, 96, 139–46.
   Google Scholar